Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

My husband is in need of bispecific treatment. Is anyone currently on bispecific antibody treatments? If so, how is it going?

A MyMyelomaTeam Member asked a question 💭
February 22, 2025
 · 
Be the first to react
A MyMyelomaTeam Member

I started treatment with Tecvayli in CHU Bordeaux a month ago,with a visit to hospital FOfor 5 days for the 3 initial doses and as precaution against possible serious side effects.I was lucky that I had no detectable side effects,in fact I cannot tell I am taking it.
I have returned for 2 weeks for further injections and still have no reactions.
It is too early for me to be given any results so I have no idea if it suppressing the Myeloma activity.
Diagnosed 8 years ago and and after various treatments ended on Daratumumab for 3 years of remission until recently when the myeloma reactivated.

July 21, 2025
A MyMyelomaTeam Member

Hello TeeMaughan, I have not tried them (teclistamab (Tecvayli), elranatamab (Elrexfio), and talquetamab (Talvey)) but my friend at the oncology center has tried Tecvayli with very positive results. She is amazed how well it is working for her.

February 22, 2025
MyMyelomaTeam

Bispecific T-cell engagers (BiTEs) are an exciting newer treatment option for multiple myeloma. These treatments work by helping your immune system fight cancer cells more effectively. They act like bridges connecting immune cells to myeloma cells, making it easier for your body to destroy the cancer.

The FDA has approved Show Full Answer

Bispecific T-cell engagers (BiTEs) are an exciting newer treatment option for multiple myeloma. These treatments work by helping your immune system fight cancer cells more effectively. They act like bridges connecting immune cells to myeloma cells, making it easier for your body to destroy the cancer.

The FDA has approved several BiTE treatments including Tecvayli (teclistamab-cqyv) in 2022 and Talvey (talquetamab) in 2023. Clinical results have been promising - for example, Tecvayli showed a 62% overall response rate in trials. One advantage of BiTE treatments is that they're "off the shelf" and readily available, unlike some other therapies that need to be specially manufactured for each person. They're typically considered after other treatments have been tried, specifically for people who have already undergone at least three previous lines of therapy.

It's recommended to discuss with your oncology specialist about whether BiTE therapy would be appropriate for your husband's specific situation.

February 22, 2025

Related Questions

View All

Is anyone involved in bispecific antibody treatment after car-t?

A MyMyelomaTeam Member asked a question 💭
Tarpon Springs, FL
December 19, 2025

Bispecifics for Relapsed and Refractory Multiple Myeloma Patients

A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA
June 13, 2025

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment
Amyloidosis: How Is It Different From Multiple Myeloma?
Plasmacytoma: Is It Different From Myeloma?